Sloan Kettering Surgeon Singer Reaches 200 Publications Including Cell, Lancet Papers

Samuel Singer, MD, a Harvard-trained surgeon who has been a Professor of Surgery at Memorial Sloan Kettering Cancer Center since 2008, has published 200 accepted research papers, according to his Scholars profile at Weill Cornell Medicine — with new studies already appearing in journals this year.

The profile, maintained on Scholars, Weill Cornell Medicine’s faculty research portal, also lists Singer as a professor of surgery with a B.S. in mechanical engineering from the Massachusetts Institute of Technology in 1979, an M.D. from Harvard Medical School in 1982, and National Cancer Institute grant funding.

  • 200 accepted publications, with his research areas focused on soft tissue neoplasms, neoplasm recurrence, local, and gastrointestinal stromal tumors.
  • 2026 papers spanning various journals.
  • NCI project funding running from 1997 through 2029, per NIH RePORTER records cited on the profile.

The output includes a Phase 2 study of palbociclib plus retifanlimab in advanced dedifferentiated liposarcoma, published in the Journal for Immunotherapy of cancer, and a paper in Cell describing how a uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

He also appears on a reanalysis of the STRASS randomised trial published in The Lancet. Digital health, identifying subsets of patients with retroperitoneal sarcoma who benefit from radiotherapy, and on a Briefings in bioinformatics paper on contextual evaluation of microRNA sequencing data harmonization for sample clustering.

That is publications across immunotherapy, radiotherapy, genomics, and computational biology, all from one surgical practice. The through-line is sarcoma: rare cancers of connective tissue.

The profile’s topic breakdown shows where Singer’s work has concentrated. Soft tissue neoplasms lead with 26 papers, followed by neoplasm recurrence, local with 20 and gastrointestinal stromal tumors with 18.

Recurrence ranking second is telling. The liposarcoma trials — including overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma, published in ESMO open — target this population.

The NIH RePORTER records on the profile trace a funding arc. Singer has been principal investigator on a Soft Tissue Sarcoma Program Project since 1997, on P50CA140146-05 from 2010 to 2018, and currently leads Project 2: Targeting the Hippo Pathway in Genetically Complex Sarcomas, an NCI award running from 2018 to 2029.

He was also PI on the acquisition of a SOLiD 3 sequencer from 2010 to 2011.

Alongside his Memorial Sloan Kettering role, Singer co-authored a The Journal of pathology paper on novel genomic risk stratification model for primary high-grade malignant peripheral nerve sheath tumor (MPNST) with Ping Chi, and appears on a Cancer research deep-learning paper, ScVital Enables Species-Agnostic Integration of Cancer Cell States, with William Douglas Tap and Doron Betel.

The Scholars page is a record, not a narrative. It lists no current clinical-trial enrollment figures, no commentary on whether the palbociclib combination results will move toward regulatory review, and no detail on the Hippo pathway project beyond its title and one linked publication. Those questions remain open on the record as it stands.

What the record does show is a career measured in volume and continuity: 200 papers, funding that has run to 2029, and a publication slate that reaches from the operating theater to machine learning. The next dated marker on file is that NCI award’s horizon — 2029.

Photo of author

Entertainment Desk

Entertainment Desk at Archyde.

New UK AD-SMART Trial Tests Repurposed Drugs to Accelerate Alzheimer’s Treatment Search

Web Summit Firm Seeks Retrospective Approval for Red Facade on Protected Dublin Building